Mode
Text Size
Log in / Sign up

Vitamin A Supplementation at Birth Alters Vaccine Immune Responses Without Improving Antibody Levels in Infants

Vitamin A Supplementation at Birth Alters Vaccine Immune Responses Without Improving Antibody Levels…
Photo by CDC / Unsplash
Key Takeaway
Recognize that Vitamin A at birth alters immune markers without improving antibody responses in infants.

This randomized, placebo-controlled intervention trial evaluated the impact of neonatal Vitamin A supplementation on vaccine responses. The study enrolled 306 infants in Dhaka, Bangladesh. Participants received 50,000 IU Vitamin A given within 48 h of birth or placebo. Follow-up assessments occurred at 6 w, 15 w and 2 y.

Primary outcomes included response to Bacillus Calmette Guérin, oral polio virus, Tetanus Toxoid and Hepatitis B virus vaccines. Antibody responses to vaccines showed no effect. Secondary outcomes assessed delayed-type hypersensitivity at 15 w for BCG. DTH response to BCG increased in infants above the birthweight median. CD4 T-cell stimulation index for BCG and SEB were reduced. TT- and HBV-specific IL-2 and IL-5 increased. SEB-stimulated IL-5 increased in girls but decreased in boys. BCG-specific IL-13 increased in girls. TT-specific and SEB-stimulated IL-17 decreased in boys. IL-10 in response to BCG, HBV below birthweight median only and SEB decreased. T-cell proliferation and cytokine production were measured at 6 w, 15 w and 2 y.

Safety data regarding adverse events, serious adverse events, discontinuations and tolerability were not reported. Limitations and practice relevance were not reported. The mixed immune findings suggest complex interactions without clear clinical benefit. Further research is needed to determine utility. Clinicians should note the lack of safety information when considering this intervention.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Vitamin A (VA) deficiency impairs immune function. STUDY DESIGN: A randomized, placebo-controlled intervention trial, stratified by sex and birthweight median (BWM), was conducted in 306 infants in Dhaka, Bangladesh to evaluate the effect of 50,000 IU VA given within 48 h of birth on responses to Bacillus Calmette Guérin (BCG), oral polio virus (OPV), Tetanus Toxoid (TT) and Hepatitis B virus (HBV) vaccines. METHODS: VA, BCG and OPV were administered within 48 h of birth. OPV was again administered at 6, 10 and 14 w with TT and HBV. Vaccine-specific responses included delayed-type hypersensitivity (DTH) at 15 w for BCG and antibody responses at 15 w (ex vivo PBMC secretion) and 2 y for OPV (IgA, IgG), TT (IgG) and HBV (IgG). T-cell proliferation and cytokine production (IFN-γ, IL-2, -4, -5, -10, -13 and -17A) in response to vaccine antigens and a polyclonal stimulus (staphylococcus enterotoxin B [SEB]) were measured at 6 w, 15 w and 2 y. Statistical analysis determined main effects of the intervention, and interactions with sex and birthweight. RESULTS: VA increased the DTH response in infants above the BWM but did not affect antibody responses to vaccines. The CD4 T-cell stimulation index (SI) was reduced by VA for BCG (6 w) and SEB (overall). VA increased TT- and HBV-specific IL-2 and IL-5 at 15 w and increased SEB-stimulated IL-5 in girls but decreased IL-5 in boys at 15 w. VA increased BCG-specific IL-13 and SEB-stimulated IL-5 in girls. VA decreased TT-specific and SEB-stimulated IL-17 in boys and decreased IL-10 in response to BCG, HBV (below BWM only) and SEB at 15 w. CONCLUSIONS: Neonatal VA modestly improved the DTH response to BCG but had no effect on antibody responses to OPV, TT and HBV. VA affected CD4 T-cell function, at times in a sex-specific manner. TRIAL REGISTRY: This trial is registered at Clinical. TRIALS: gov. Registry numbers are NCT015839720 and NCT02027610.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.